Advertisement

Topics

Progress Toward Regional Measles Elimination - Worldwide, 2000-2017.

07:00 EST 30th November 2018 | BioPortfolio

Summary of "Progress Toward Regional Measles Elimination - Worldwide, 2000-2017."

In 2010, the World Health Assembly set three milestones for measles prevention to be achieved by 2015: 1) increase routine coverage with the first dose of measles-containing vaccine (MCV1) among children aged 1 year to ≥90% at the national level and to ≥80% in every district; 2) reduce global annual measles incidence to less than five cases per million population; and 3) reduce global measles mortality by 95% from the 2000 estimate (1).* In 2012, the World Health Assembly endorsed the Global Vaccine Action Plan (GVAP), with the objective of eliminating measles in four of the six World Health Organization (WHO) regions by 2015 and in five regions by 2020. Countries in all six WHO regions have adopted goals for measles elimination by 2020. This report describes progress toward global measles control milestones and regional measles elimination goals during 2000-2017 and updates a previous report (2). During 2000-2017, estimated MCV1 coverage increased globally from 72% to 85%; annual reported measles incidence decreased 83%, from 145 to 25 cases per million population; and annual estimated measles deaths decreased 80%, from 545,174 to 109,638. During this period, measles vaccination prevented an estimated 21.1 million deaths. However, measles elimination milestones have not been met, and three regions are experiencing a large measles resurgence. To make further progress, case-based surveillance needs to be strengthened, and coverage with MCV1 and the second dose of measles-containing vaccine (MCV2) needs to increase; in addition, it will be important to maintain political commitment and ensure substantial, sustained investments to achieve global and regional measles elimination goals.

Affiliation

Journal Details

This article was published in the following journal.

Name: MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Pages: 1323-1329

Links

DeepDyve research library

PubMed Articles [10524 Associated PubMed Articles listed on BioPortfolio]

Measles Outbreak in a Highly Vaccinated Population - Israel, July-August 2017.

On August 6, 2017, the Israeli Defense Force Public Heath Branch (IDFPHB) was notified of two suspected measles cases. IDFPHB conducted an epidemiologic investigation, which identified nine measles ca...

Measles and Rubella Seroprevalence in Mother-Infant Pairs in Rural Nepal and the United States: Pre- and Post-Elimination Populations.

We sought to compare seroprevalence of protective measles and rubella-specific antibody in mother-infant pairs across two populations: a pre-disease elimination Nepal population with recently introduc...

Formation of the Asian Rabies Control Network (ARACON): A common approach towards a global good.

The drive towards the worldwide elimination of dog-mediated human rabies by 2030 is the first step towards the ultimate goal of dog rabies elimination - as dogs account for more than 99% of human rabi...

Modeling the Effectiveness of Infection Control Measures for the Elimination of Measles: Focus on Adults Born After 1970.

The German National Action Plan for the implementation of the WHO goal of measles elimination still faces considerable challenges regarding reaching its goal of increasing adult's vaccination rates an...

Measles immunity in an Italian teaching hospital.

Healthcare workers (HCWs) have an increased exposure risk to measles, which can put them, their patients and their relatives at risk of infection. In Italy, 4617 cases of measles were reported in 2017...

Clinical Trials [3660 Associated Clinical Trials listed on BioPortfolio]

Prophylactic Antibiotics in Measles

Objective It is the objective to test whether the use of prophylactic antibiotics in measles infection will reduce the incidence of post-measles pneumonia and/or admissions to hospital wit...

Immunology of Non-Specific Effects of Vaccine

OBJECTIVES - General: To investigate the immunological background for the non-specific effects of diphtheria-tetanus-pertussis (DTP) and measles vaccines on child mortality ...

Mass Drug Administrations of DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique

In line with the global and regional efforts towards malaria elimination, a five year program was established to assist the NMCP in adopting targeted evidence-based elimination plans throu...

Non-Specific Effects of Standard Titre Measles Vaccination

The general objectives of the proposed research work are: A1) to reduce childhood mortality in developing countries through better control of measles infection by finding the best immuniz...

Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines

Japanese encephalitis (JE) is the leading cause of viral neurological disease and disability in Asia. A live attenuated vaccine (LJEV) manufactured in China has several advantages over oth...

Medical and Biotech [MESH] Definitions

A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)

The type species of MORBILLIVIRUS and the cause of the highly infectious human disease MEASLES, which affects mostly children.

A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.

Planning for health resources at a regional or multi-state level.

A rare, slowly progressive encephalitis caused by chronic infection with the MEASLES VIRUS. The condition occurs primarily in children and young adults, approximately 2-8 years after the initial infection. A gradual decline in intellectual abilities and behavioral alterations are followed by progressive MYOCLONUS; MUSCLE SPASTICITY; SEIZURES; DEMENTIA; autonomic dysfunction; and ATAXIA. DEATH usually occurs 1-3 years after disease onset. Pathologic features include perivascular cuffing, eosinophilic cytoplasmic inclusions, neurophagia, and fibrous gliosis. It is caused by the SSPE virus, which is a defective variant of MEASLES VIRUS. (From Adams et al., Principles of Neurology, 6th ed, pp767-8)

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topics

Measles
Measles (morbilli, rubeola) is a highly infectious viral illness that can be very unpleasant and can sometimes lead to serious complications.  The initial symptoms of measles develop around 10 days after initial infection: a high temperature (...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Searches Linking to this Article